GO
Loading...

Stock Chatter Focuses on Financials, Pharma

Brooke Sopelsa,|Video Producer
Friday, 18 Jul 2008 | 2:01 PM ET

Pharmaceutical stocks and financial shares are getting attention on Wall Steet following the recent Wednesday-Thursday rally.

Friday Trade
Preparing your portfolio for next week, with Steve Grasso, Stuart Frankel and John O'Donoghue, Cowen & Co.

Betting on Pharma

If you think about the aging community…med-tech is obviously a place that still is attracting both value and growth…so the Baxters , the JNJs , which are breaking out through 52-week highs here, continue to be in pretty good shape. They’ve got great balance sheets, and with reimbursement rates still where they are, these stocks are still going to work.

John O'Donoghue, Cowen & Co.

How to Play Merrill & Citi Now
Positions on these financials, with David Katz, Matrix Asset Advisors chief investment officer and CNBC's David Faber

How to Play Merrill Lynch

“Even with all the problems, Merrill Lynch is earning about $4 a share. We think in a normal time they can earn up to $5 a share. At $28 or $30 stock price, you’re getting a very good company at a very reasonable price.”

David Katz, Matrix Asset Advisors Chief Investment Officer
(Contd.)

______________________________________
Stay up-to-date:

______________________________________

Market Pulse Check
Market watchers weigh in on whether we are near a bottom, with Wendell Perkins, Optique Capital Management and James Paulsen, Wells Capital Management

Tiptoeing in Financials

"For investors that would like to tiptoe into the financials, and want to do so conservatively, clearly, the report from JPMorgan Chase was very encouraging ... Also, a great bank in North Carolina, BB&T, very strong credit culture, very solid quarter under the circumstances."

Wendell Perkins, Optique Capital Management

Perkins also likes: Citigroup.

  Price   Change %Change
BAX
---
BBT
---
C
---
JNJ
---
JPM MLP ETN
---

Featured

Contact Stocks

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More